Treatment Patterns and Healthcare Resource Use Among Patients With Axial Spondyloarthritis and Comorbid Inflammatory Bowel Disease

Author(s)

Song C1, Hopson S2, Marden JR3, Sarathy K3, Swallow E3, Beaty S2
1UCB Pharma, Duluth, GA, USA, 2UCB Pharma, Smyrna, GA, USA, 3Analysis Group, Inc., Boston, MA, USA

Presentation Documents

OBJECTIVES: Biologics approved for both axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) may optimize outcomes among axSpA/IBD patients.

This research describes real-world characteristics and treatment patterns of newly diagnosed axSpA patients (stratified by comorbid IBD).

METHODS: Retrospective cohort study using IBM® MarketScan® database (Commercial and Medicare Supplemental). Eligible adults had ≥1 axSpA diagnosis from 01/2015–03/2020. Index was first recorded axSpA diagnosis with 12-month baseline. Patients were followed to end of study/loss of eligibility. Descriptive analyses performed.

RESULTS: Study included 397,735 axSpA patients, 2% (n=6,628) had baseline IBD (axSpA/IBD). Among axSpA/IBD patients, 55% had ulcerative colitis and 54% had Crohn’s disease (9% had ulcerative colitis/Crohn’s disease); mean age was 51 years, 63% were female, and 86% were commercially insured (88% had non-capitated health plans).

Among axSpA/IBD patients, mean (standard deviation) Charlson comorbidity index was 0.88 (1.40) versus 0.62 (1.21) for patients without IBD. axSpA/IBD patients had higher proportion of anxiety (24% versus 18%), chronic pulmonary disease (18% versus 15%), and mild liver disease (10% versus 4%) than patients without IBD. Prior medication use was greater among axSpA/IBD patients (opioids [53% versus 44%], corticosteroids [52% versus 34%], mesalamine derivatives [41% versus 1%], and biologics [28% versus 1%]).

Of axSpA/IBD patients who received biologics during follow-up (n=2,117), 88% received axSpA/IBD‑indicated biologics, 16% IBD-indicated, and 3% axSpA-indicated. Most patients maintained biologics for the same indications through follow-up (maintenance rates: 82% axSpA/IBD; 83% IBD; 68% axSpA).

Less than 1% of patients switched to biologics with different indication; 81% switched from axSpA/IBD- to IBD-indicated biologics. Among axSpA/IBD patients, 8% initiated biologics after index, of which 87% received axSpA/IBD‑indicated biologics.

CONCLUSIONS: Understanding treatment journey for axSpA/IBD patients may inform treatment decisions. axSpA/IBD patients had greater baseline disease burden versus patients without IBD. Most axSpA/IBD patients used axSpA/IBD‑indicated biologics during baseline and maintained through follow-up.

Conference/Value in Health Info

2024-05, ISPOR 2024, Atlanta, GA, USA

Value in Health, Volume 27, Issue 6, S1 (June 2024)

Code

HSD32

Topic

Real World Data & Information Systems

Topic Subcategory

Health & Insurance Records Systems

Disease

Gastrointestinal Disorders, Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×